Within a cohort of 12 PD patients on LCIG, Foltynie et al. described one LRRK2 carrier treated with LCIG after a 19-year history of PD and a previous unsuccessful attempt with DBS. This evidence concerns the gene LRRK2 and Parkinson disease.